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Abstract: Molecules containing tetrazole substituents have become of interest due to their being bioisosteres of 
carboxylic acids and like their carboxylate counterparts, tetrazolate anions have been able to affect the crystal growth 
of barium sulphate and calcium carbonate. In this proof of principle study, we show that this behaviour also extends 
to calcium oxalate and therefore opens the possibility of using tetrazole-based additives for investigating 
mineralization processes of human pathological relevance. 
Introduction 
 
Biomineralization encompasses many biological crystallization events 
including urolithiasis (the formation of stones in the urinary tract).1 
Thus, the formation of kidney stones is an undesired biomineralization 
event within human bodies. Calcium oxalate, calcium phosphate and 
uric acid constitute 89% of renal calculus, commonly known as 
kidney stones. Calcium oxalate dominates the constituents of kidney 
stones at 70%.2 Calcium oxalate has three hydrate forms, with calcium 
oxalate monohydrate (COM, CaC2O4∙H2O) being the 
thermodynamically stable phase. Calcium oxalate dihydrate (COD, 
CaC2O4∙2H2O) and calcium oxalate trihydrate (COT, CaC2O4∙3H2O) 
are the meta-stable phases. All three crystal phases can be found 
within kidney stones. 
 
The formation of kidney stones causes extreme pain in patients and 
currently the lifetime risk of developing a kidney stone is 10-15% in 
the developed world and up to 20-25% in the Middle East.3 The 
current best-practises in dealing with kidney stones are medical 
expulsive therapy (MET) and shock-wave lithotripsy (SWL) both of 
which are not methods of prevention but rather are aimed at 
spontaneous passage of formed ureteral calculi, and ultrasound 
degradation of the particles too big for passage. The best 
pharmaceutical treatments include the use of hydrochlorothiazide, 
chlorthalidone or indapamide which act as thiazide or thiazide-like 
diuretics and inhibit the kidneys ability to retain water; these drugs 
however have potential drawbacks associated to the risk of 
hypotension (low blood-pressure) and hypokalemia (potassium 
depletion).4,3 Not surprisingly, major effort has been devoted to 
controlling the size and shape of the calcium oxalate with the aim of  
finding better strategies to deal with this condition.  
 
Crystal growth modifiers are additives that can be used to gain control 
over crystallization processes, either in the form of promotion or 
inhibition. To date, a variety of additive types including; 
calixarenes,5,6 glycosaminoglycans,7 double-hydrophilic block 
copolymers,8 phospholipid monolayers,9 amino acids, proteins and 
carboxylic acids have been shown to impact the crystallization of 
calcium oxalate.10 Our previous work investigated the use of 
tetrazoles as crystal growth modifiers for inorganic solids. We showed 
that both the crystallization of barium sulphate and calcium carbonate 
are impacted on by tetrazoles in a unique way compared to their 
parent carboxylic acids.11 In this manuscript, we report a proof of 
principle study to determine whether tetrazoles can impact on the 
crystallization of calcium oxalate and if they do so at comparable 
levels to carboxylic acid. Thus, this is a first step in determining 
whether tetrazoles might hold any potential for crystal growth 
modification of biologically important minerals.  
 
The methods of synthesising tetrazoles has been extensively 
researched12–19 due to the multitude of applications of tetrazole-
containing compounds, including the use of tetrazoles in materials 
science and medicinal chemistry.20,21 Tetrazoles have been 
increasingly used in medicine due to their bioisostere nature with 
carboxylic acids.22 Carboxylic acids and tetrazoles are isosteres due to 
their similar pKa values resulting from their dissociation (details on 
the pKa’s calculated or known for the molecules investigated in this 
work can be found in Table S4† in the supplementary information). 
Thus it has become possible to replace the carboxylic acid functional 
group with that of the tetrazole ring for medicinal applications such as 
anti-asthmatic and anti-cancer drugs.23,24 An important aspect of this 
replacement is due to the tetrazole being a more metabolically stable 





Figure 1 shows the structures of the tetrazole molecules and 
carboxylic acid equivalents investigated in this work. All of the 
tetrazoles were prepared following a previously reported procedure,19 
involving the [1,3] dipolar cycloaddition of the corresponding nitrile 
with sodium azide (NaN3) in the presence of triethylammonium 
hydrochloride. The tetrazole-containing carboxylic acid (TzBaH2) 
was synthesised by selective hydrolysis in aqueous sodium hydroxide 
at room temperature from the ester, 4-(1H-tetrazol-5-yl) benzoate.  
Fig. 1 The tetrazole-substituted additives and carboxylic acids 
investigated in this work: 5-phenyl-1H-tetrazole (TzPhH), 4-(1H-
tetrazol-5-yl)benzaldehyde (TzPhaH), 4-(1H-tetrazol-5-
yl)benzonitrile (TzPhCNH), 1,4-bis-(1H-tetrazol-5-yl)benzene 
(TzTzH2), benzoic acid (BaPhH), 4-formylbenzoic acid (BaPhaH), 
4-cyanobenzoic acid (BaPhCNH), terephthalic acid (BaBaH2), 4-
(1H-tetrazol-5-yl)benzoic acid (BaTzH2). 
 
Crystallization of calcium oxalate methodology 
Stock solutions of the starting two reagents (calcium chloride and 
sodium oxalate) were prepared. To a flask (250 mL), calcium chloride 
(0.444 g, 0.004 mol) was added into ultrapure water (200 mL) to 
make the stock calcium chloride solution (0.02 mol L-1). Next, sodium 
 
 
oxalate (0.536 g, 0.004 mol) was added to ultrapure water (200 mL) in 
a 250 mL flask to make the stock sodium oxalate solution (0.02 mol 
L-1), with the use of a sonicator when necessary. Stock solutions of the 
modifying species (tetrazoles or carboxylic acids) were made up to 
10 g L-1 concentrations, at pH 7 (adjusted to ~pH 7 by 1.0 M sodium 
hydroxide solution), ready for addition. To obtain the calcium oxalate 
crystals (300-500 µL) of the calcium chloride solution was added to 
20 mL glass vials as required. Cleaned glass discs with a radius of 0.5 
cm were placed at the bottom of each vial to provide a removable 
crystal growth site. Next the required amount of modifier was added 
to the flask followed by the addition of ultrapure water, almost up to a 
final volume (20 mL). The solution was equilibrated in a water bath to 
the reaction temperature, 30°C, before the addition of sodium oxalate 
solution (equimolar, 300-500 µL) to begin the reaction. The vials 
were left in the 30°C water bath for 3 days before the glass disc from 
each sample vial was removed and the excess fluid adsorbed using 
tissue paper. The glass vial was then placed in a new, dry sample vial 
for analysis. All samples had a constant final volume of 20 mL and 
pH ~7. The final concentrations of calcium oxalate in the vials ranged 
between 1.0 x 10-4 M and 5.0 x 10-4 M, but the results for a final 
concentration of 0.30 mM are presented here. All the experiments and 
the number of repeats are given in the supplementary information 
(Tables S1† and S2†). 
Scanning electron (SEM) and optical microscopy  
SEM was performed at the Curtin University Electron Microscope 
Facility using a Zeiss Evo 40XVP SEM using either secondary 
electron or back-scatter detectors. Energy-dispersive X-ray 
spectroscopy (EDX) was also employed in determining the qualitative 
composition of our samples. Each sample analysed by SEM was 
coated with either gold or platinum.  
 
Measurement of size from SEM images 
Each SEM image used in either the manuscript or supplementary 
information was run through the free software, ImageJ, to determine 
the number of particles, their size and standard deviation of particles 
from the mean. The measuring tool and scale bar calibration was used 
to measure the length (c-axis length) and width of each particle in the 
SEM image. Table S1† in the supplementary information was 
generated from the collection of this data. 
 
Confocal Raman Spectroscopy 
While XRD would have been the characterization method of choice to 
determine the different hydrates of calcium oxalate formed, the small 
amount of solids present meant this technique was not appropriate. 
Thus, Raman, which has also been shown to be specific to mineral 
form and chemistry, was used instead.26–29  
 
The Confocal Raman Spectroscopy (CRM) and Scanning Near-Field 
optical Microscopy (SNOM) measurements were obtained using the 
WITec alpha 300SAR utilising a frequency-doubled NdYAG laser of 
wavelength 532 nm and of 50 mW power. Each Raman spectrum 
collected consists of 10 accumulations at an integration time of 
0.08371 seconds and a grating of 600 g/mm. Analysis was performed 
using the WITec Project FOUR software.  
 
Complexation experiments 
Commercially obtained COM was added in excess (0.25 g, 
1.71 mmol) to 50 mL vials with varying concentrations of organic 
additives (0-5 g/L), filled with ultrapure water and left for 1 week at 




Fig. 2  SEM image of calcium oxalate monohydrate control 
particles (0.30 mM) solution. 
 
After 1 week, the filtrate was collected by vacuum through 0.2 µm 
filter membranes for analysis. Inductively coupled plasma-atomic 
emission spectroscopy (ICP-AES) analysis was recorded on a Varian 
Vista Axial CCD ICP-AES at Murdoch University’s Centre for 
Marine and Freshwater Research Laboratory. 
 
Timed experiments 
All conditions were the same as mentioned in the crystallization of 
calcium oxalate except that the samples were removed at different 
time periods up to a time of 1 month. The additives investigated were 
TzPh
-
 (6.84 mM) and BaPh- (8.18 mM) as further investigation into 
the dissolution mechanism occurring in the presence of the phenyl-
tetrazole species TzPh- was required. 
 
Turbidimetric methodology 
Ultrapure water (3.48 mL) was added to a ~5 mL cuvette and a 
background reading was recorded before the addition of organic 
additive (0.40 mL), calcium chloride and sodium oxalate solutions 
(60 µL each) before the turbidity was monitored for thirty minutes. 
Turbidity was measured by using a UV-vis instrument (GBC Double 
beam UV/VIS Spectrophotometer 916) at 900 nm at an integration 
time of 0.5 seconds and slit width of 2.0 nm for all samples. All 
samples were filtered through a 0.1 µm membrane filter to remove 
any particles in the solution that would provide a seed for nucleation. 
The final concentration of calcium oxalate in the cuvettes was 3.0 x 
10-4 M. Turbidity experiments were conducted multiple times and 
averaged to give the final curve for induction time determination. 
 
Results and discussion 
 
Control calcium oxalate monohydrate 
In order to determine the impacts of both the tetrazole containing and 
the carboxylate containing molecules many control samples were 
imaged and analysed. Figure 2 shows an SEM of the typical control 
crystals with COM morphology. As previously mentioned, COM is 
the thermodynamically stable phase for calcium oxalate and thus 
would be the expected product after 72 hours.  These particles were 
confirmed as COM by confocal Raman spectroscopy (see 
supplementary information, Figures S1† and S2†). The mean length 
of the control particles was found to be approximately 7 µm in length. 
 
 
No fluorescence was observed in the presence of COM for all laser 
strengths applied. Supplementary Figure S3† illustrates the crystal 
face indexing for COM used throughout this manuscript30. 
 
Impact of carboxylic acid derivatives as compared to tetrazole 
derivatives on calcium oxalate crystallization 
Figure 3 presents the comparison between some of the carboxylic acid 
and tetrazole additives on calcium oxalate crystallization in this study. 
The impact of tetrazole additives are all shown on the left side of 
Figure 3, while their carboxylic acid equivalent groups are shown on 
the right hand side. Starting from the top, both additives with an 
aldehyde functional group; Figures 3a (TzPha-) and 3b (BaPha-) 
formed calcium oxalate crystals with shortened crystal lengths in the 
[001] direction (c-axis) compared to the control samples previously 
seen. Upon close inspection, some crystals (Fig. 3a) are devoid of the 
{010} face and there is no twinning resulting in some cube shaped 
crystals (see Fig. S4† for a magnified view of Fig. 3a). While both 
additives have modified the crystallization of calcium oxalate, the 
TzPha
- additive was found to have altered the crystal shape and 
increased the average particle length to ~16.5 µm (see Table S1† in 
supplementary information). BaPha-, on the other hand, decreased the 
average particle length and number of particles compared to the 
control.  
 
The addition of TzTz2- resulted in some crystals with shortened c-axis 
lengths (Fig. 3c) whilst the presence of BaBa2- (Fig. 3d) resulted in 
crystals more than twice the size of the control samples (see Table 
S4†). The c-axis or [100] direction corresponds to the thickness of the 
crystal, implying that the tetrazole has impacted on growth in this 
direction. The final images show calcium oxalate crystals in the 
presence of TzPh- and BaPh- (Fig. 3e and 3f, respectively). The 
tetrazole species has impacted the COM crystals by “hollowing out” 
the crystal centre on the {100} face through the entire crystal width. 
Investigating the possible means by which the tetrazole does this is 
discussed later. The carboxylic acid additive on the other hand, 
showed no signs of this “hollowing out” and did not show significant 
signs of morphological impact or alteration of the aggregation state of 
the crystals. Both species TzPh- and BaPh- had similar gross 
morphology and mean particle sizes (Table S1†) indicating that 
preferential adsorption onto specific crystal faces does not appear to 
be occurring.  
 
The species, TzBa2- showed only weak signs of inhibiting calcium 
oxalate crystallization (see Fig. 4, S5†) and these were determined to 
be COM by Raman. The morphology of those particles that were not 
broken does not appear to be significantly different to the control 
particles, and the average length of the particles in the presence of this 
additive was found to be ~6 µm compared to the control length of 
~7 µm, which is within the standard deviation of the measurements. 
 
The presence of TzPhCN- (Fig. 5a) showed a similar action to that 
when BaPhCN- (Fig. 5b) additive was present, the additives 
appearing to have a significant impact on growth in the [100] (the 
thickness of the crystal). In the presence of both these additives the 
calcium oxalate crystals formed are significantly thinner than the 
control crystals. This is most probably due to inhibition on the {100} 
crystal face by the additive resulting in the relative growth rate of the 
{100} being much slower than perpendicular to this axis. The 
presence of TzPhCN- appears to have a greater impact than BaPhCN- 
on the size as confirmed by the quantitative data (see Table S1†). At 
the lower concentration of 1 g/L of additive, the COM particles are 




To better determine the impact of these small molecules on the 
nucleation behaviour of calcium oxalate, we undertook turbidimetric 
studies to assess their impact on homogenous nucleation. Turbidity 
was used to monitor the onset of nucleation and the induction time 
from these experiments determined. The important parameter in these 
studies is not the turbidity (which is impacted by many factors such as 
size, shape and number of particles)33,34 but the induction time, which 
is the time the turbidity increases above baseline.35 Induction time is 
inversely related to the homogenous nucleation rate. Increasing 
induction time suggests that the organic molecules are adsorbing onto 
the nuclei and changing their surface free energy (provided 
supersaturation is not significantly altered).36 Due to the small 
volumes and low concentrations used in this study, there was 
significant scatter in the turbidimetric data, thus 4-6 data sets were 
averaged to minimise these errors. The complete set of turbidity 
curves can be found in the supplementary information along with the 
induction time shown by an arrow (Fig. S8†- S16†). The most 
important information, however, was in how the presence of additives 
altered the nucleation rate compared to the control, thus trends are 
more important than the actual values. The control sample (Fig. S14†) 
showed an induction time of between 25-35 seconds based on the time 
required for the turbidity to rise above the background. When the 
additive TzTz2- (Fig. S15†) was present during crystallization the 
induction time was found to be ~10 seconds. In comparison the 
presence of BaBa2- (Fig S16†) was found to have an even shorter 
induction time, almost occurring instantaneously, at ~5 seconds. 
 
None of the tetrazole additives showed a significant lengthening of the 
induction time. In fact, for most of the tetrazole additives the opposite 
was found. Two tetrazoles, TzPh- and TzPha-, showed similar 
induction times to the control. In addition, this result suggests that 
despite the fact that the doubly charged additives complex more with 
calcium in solution (see section below on solution behaviour) they do 
not lower the nucleation rate of calcium oxalate monohydrate. For the 
carboxylate molecules, BaPh-, BaPhCN- and BaPha-, each was found 
to promote nucleation somewhat with induction times of 15-25 
seconds, 5-15 and 10-15 seconds, respectively. Similar to the 
tetrazoles then, the carboxylic acid derivatives appear to promote 
nucleation slightly. 
 
The ability of the tetrazoles to complex calcium was investigated to 
determine whether the modifiers altered supersaturation significantly 

































Fig. 3   SEM images of calcium oxalate (0.30 mM) formed in the presence of (a) 1.0 g/L (5.74 mM) TzPha-, (b) 1.0 g/L 



















Fig. 4 SEM image of calcium oxalate (0.30 mM) particles formed 


























Fig. 5 SEM image of calcium oxalate (0.30 mM) particles formed 




The ability of the various molecules to complex calcium was 
undertaken by measuring the dissolution of commercially obtained 
COM with the six inhibitors highlighted in Figure 6, in ultrapure 
water. The calcium content after a week was analysed by ICP-AES, 
which determined that increased solubility by complexation did not 
significantly occur for many of the molecules (Fig. 6), in particular in 
the presence of TzPh-. However, it was shown from this data set that 
the TzTz2-, BaBa2- and TzBa2- additives showed significant increases 
in the dissolution of calcium oxalate monohydrate compared to the 
other additives analysed (see S3† for concentration information). The 
molecules containing more than one functional group, therefore, 
would change the supersaturation solutions and may account for the 
observed morphological impacts in the presence of these additives. 
 
In addition, since the tetrazole, TzPh-, does not significantly complex 
calcium the “hollowing out” does not appear to be due to subsequent 
complexation and dissolution. 
 
Fig. 6 Dissolution of Ca2+ from COM in the presence of additive 
species in solution measured by ICP-AES. 
 
Timed experiments: 
Prolonged timed experiments were conducted to determine if,  
i) in the presence of the additive TzPh-, the crystals grew 
in the hollowed out manner and 
ii) after the COM dissolved whether some other solid 
phase re-precipitated.  
 
Initially, the majority of particles formed were the thermodynamically 
stable COM (see Fig. S17a†) having a morphology that is also 
equivalent to the control particles. Particles larger in mean length than 
an average control sample were obtained according to the quantitative 
data; standard COM control crystals usually averaged ~7µm in length 
while in the presence of the tetrazole average lengths from 9-22 µm 
were observed in different repeats. After >3 days dissolution of the 
interior of the particles can be observed (as shown in Fig. 17b) and is 
a reproducible affect seen in Fig. 3e, Figures S18† and S19†. 
 
No evidence of calcium oxalate re-precipitation is observed of any 
form. After 19 days few particles with COM shape remained, and 
there is microbial action evident as the laboratory conditions were not 
sterile. This issue persisted even when we attempted to sterilise by 
filtration (filtering all solutions using a 0.2 µm pore membrane). 
Experiments with azide are currently underway. The timed 
experiments did show that the crystals did not grow in a hollowed 
manner from the beginning but were in fact similar to control crystals, 
however we were not able to determine any recrystallization due to 
the bacterial growth. This bacterial growth did not occur for the 
control experiment, nor in the presence of the carboxylate containing 
molecule even after 19 days (see Figures S20a† and b). 
 
Using Confocal Raman spectroscopy, the crystals taken after 3 days in 
the presence of the tetrazole; still in typical COM shape with no 
visible signs of hollowing were analysed. These particles showed a 
Raman spectrum (Fig. 21a†) with a significant degree of fluorescence 
in the background. Further investigation found that this fluorescence 
only occurred in the presence of the tetrazole molecule. In addition, 
the two main identified peaks when compared to pure TzPhH 
tetrazole at ~1360 cm-1 and ~1622 cm-1 are believed to be the tetrazole 
peaks observed at 1411 cm-1 and 1602 cm-1 for the pure tetrazole (Fig. 
S21b†) but modified by its bonding environment.37 In any event, these 
bands are different to the control COM crystal’s Raman spectrum 
(Fig. S21c†), showing the expected doublet for the monohydrate at 
1460, 1480 cm-1 and which does not emit such broad fluorescence as 
























This implies that the tetrazole species is present in the crystal prior to 
hollowing occurring. Thus, at this point the data suggests it is the 
incorporation of the tetrazole that causes the “hollowing out” by 
weakening the crystal structure at defects or areas of strain thus 
resulting in re-dissolution at these points after prolonged periods.  
 
Conclusions 
From this study we have shown that tetrazoles can impact on COM 
morphology and size significantly. Of the molecules investigated the 
TzPh
-, TzPhCN-, TzTz2- and TzPha-, were found to be the most 
potent. The faces most impacted by the tetrazoles are the {100} and 
{001} faces of COM. In all cases we found COM was formed in the 
presence of these tetrazoles, not COD, and this is thought to be due to 
the pH of the experiments falling between 6.5 and 7.5, while COD has 
been shown to form favourably in basic conditions.38 The tetrazole 
molecules were generally found to promote homogenous nucleation.  
 
The tetrazole additives throughout this study have been shown to 
impact more than their carboxylic acid equivalent groups (as lower 
concentrations are required to achieve similar or more significant 
morphological impacts) across a variety of functional groups. The 
increase in the number of functional groups from one to two tetrazole 
or carboxylic acid groups is seen to increase their impact on calcium 
oxalate crystallization as has been observed for other systems.11 
 
The “hollowing out” observed in the presence of TzPh- was 
investigated in more detail. It was found that this tetrazole does not 
complex the calcium ion to any significant extent but is present with 
the COM prior to the dissolution occurring. The timed experiments 
showed that the COM doesn’t grow in this fashion and that therefore 
the most likely mechanism is that the tetrazole is incorporated in the 
crystal and that the dissolution is due to this incorporation weakening 
the crystal structure. This is further being investigated due to 
microbial action interfering with the longer-term experiments. 
 
In conclusion, it can be stated that tetrazoles can be used as crystal 
growth modifiers of calcium oxalate monohydrate. Furthermore, we 
plan to continue research in this area to explore a variety of 
backbones, different functional groups and their stereochemistry. It 
will be interesting to investigate the differences in stereoisomers in the 
ortho and meta substituted positions in addition to further 
investigations into functional groups that are electronegative and 
electropositive; this is due to the most significant modifiers being 
identified, in this study, as those that are electron withdrawing (except 
for H in TzPh-). Experiments closer to physiological conditions and 
biologically relevant environments are also envisaged to ascertain 
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